Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Schwartz, Stanley
2014.
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes.
Postgraduate Medicine,
Vol. 126,
Issue. 3,
p.
66.
Zueger, Patrick M.
Schultz, Neil M.
and
Lee, Todd A.
2014.
Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review.
PharmacoEconomics,
Vol. 32,
Issue. 11,
p.
1079.
Deng, Jing
Gu, Shuyan
Shao, Hui
Dong, Hengjin
Zou, Dajin
and
Shi, Lizheng
2015.
Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
Journal of Medical Economics,
Vol. 18,
Issue. 11,
p.
974.
Gu, Shuyan
Deng, Jing
Shi, Lizheng
Mu, Yiming
and
Dong, Hengjin
2015.
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Journal of Medical Economics,
Vol. 18,
Issue. 10,
p.
808.
Strongman, H.
D'Oca, K.
Langerman, H.
and
Das, R.
2015.
Comparison of diabetes‐associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
Diabetes, Obesity and Metabolism,
Vol. 17,
Issue. 6,
p.
573.
Gu, Shuyan
Zeng, Yuhang
Yu, Demin
Hu, Xiaoqian
Dong, Hengjin
and
Hu, Cheng
2016.
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.
PLOS ONE,
Vol. 11,
Issue. 11,
p.
e0167190.
Roussel, Ronan
Martinez, Luc
Vandebrouck, Tom
Douik, Habiba
Emiel, Patrick
Guery, Matthieu
Hunt, Barnaby
and
Valentine, William J.
2016.
Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Journal of Medical Economics,
Vol. 19,
Issue. 2,
p.
131.
Gu, Shuyan
Mu, Yiming
Zhai, Suodi
Zeng, Yuhang
Zhen, Xuemei
Dong, Hengjin
and
Hu, Cheng
2016.
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
PLOS ONE,
Vol. 11,
Issue. 11,
p.
e0165629.
Huang, Yunyu
Vemer, Pepijn
Zhu, Jingjing
Postma, Maarten J.
Chen, Wen
and
Khamseh, Mohammad Ebrahim
2016.
Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims Data.
PLOS ONE,
Vol. 11,
Issue. 8,
p.
e0159297.
Zhang, Xuesong
Liu, Sisi
Li, Yukun
Wang, Yan
Tian, Meimei
Liu, Guoqiang
and
Atkin, Stephen L
2016.
Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
PLOS ONE,
Vol. 11,
Issue. 6,
p.
e0156393.
Hua, Xinyang
Lung, Thomas Wai-Chun
Palmer, Andrew
Si, Lei
Herman, William H.
and
Clarke, Philip
2017.
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.
PharmacoEconomics,
Vol. 35,
Issue. 3,
p.
319.
Shao, Hui
Zhai, Suodi
Zou, Dajin
Mir, Mohammed Umer
Zawadzki, Nadine K.
Shi, Qian
Liu, Shuqian
and
Shi, Lizheng
2017.
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Current Medical Research and Opinion,
Vol. 33,
Issue. 2,
p.
359.
Gu, Shuyan
Wang, Xiaoyong
Qiao, Qing
Gao, Weiguo
Wang, Jian
and
Dong, Hengjin
2017.
Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Diabetes, Obesity and Metabolism,
Vol. 19,
Issue. 12,
p.
1688.
Hong, Dongzhe
Si, Lei
Jiang, Minghuan
Shao, Hui
Ming, Wai-kit
Zhao, Yingnan
Li, Yan
and
Shi, Lizheng
2019.
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
PharmacoEconomics,
Bagepally, Bhavani Shankara
Chaikledkaew, Usa
Gurav, Yogesh Krishnarao
Anothaisintawee, Thunyarat
Youngkong, Sitaporn
Chaiyakunapruk, Nathorn
McEvoy, Mark
Attia, John
and
Thakkinstian, Ammarin
2020.
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.
BMJ Open Diabetes Research & Care,
Vol. 8,
Issue. 1,
p.
e001020.
Liu, Gordon
Huang, Zhiyong
Xin, Qian
and
Xu, Youhua
2021.
Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients.
Evidence-Based Complementary and Alternative Medicine,
Vol. 2021,
Issue. ,
p.
1.
Hu, Shanshan
Deng, Xun
Ma, Yanjiao
Li, Zhilei
Wang, Yuhang
and
Wang, Yong
2021.
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
Applied Health Economics and Health Policy,
Vol. 19,
Issue. 1,
p.
69.
Salem, Ahmed
Men, Peng
Ramos, Mafalda
Zhang, Yan-Jun
Ustyugova, Anastasia
and
Lamotte, Mark
2021.
Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Journal of Comparative Effectiveness Research,
Vol. 10,
Issue. 6,
p.
469.
Hu, Shanshan
Su, Xiaorong
Deng, Xun
and
Wang, Yong
2021.
Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.
Frontiers in Pharmacology,
Vol. 12,
Issue. ,
Hu, Shanshan
Wang, Shuowen
Qi, Chendong
Gu, Shengying
Shi, Chenyang
Mao, Lin
and
Fan, Guorong
2022.
Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
Frontiers in Pharmacology,
Vol. 13,
Issue. ,